Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer.
Takahiro TsujikawaTodd CrocenziJennifer N DurhamElizabeth A SugarAnnie A WuBeth OnnersJulie M NaurothRobert A AndersElana J FertigDaniel A LaheruKim ReissRobert H VonderheideAndrew H KoMargaret A TemperoGeorge A FisherMichael ConsidineLudmila V DanilovaDirk G BrockstedtLisa M CoussensElizabeth D ThompsonDung T LePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Although the study did not meet its primary endpoint of improvement in OS of Arm A over Arm B, the OS was comparable with standard therapy. Objective responses and immunologic changes in the tumor microenvironment were evident.
Keyphrases